The endocrine therapy is the most commonly used treatment for patients with ER+ breast tumors, which either blocks the E2 binding (tamoxifen) or stops the E2 production (aromatase inhibitors) [24, 25]. The gene discussed is ESR1; the disease is breast neoplasm.